Azalea Therapeutics: Valuation, Funding & Investors
Azalea Therapeutics is a biotechnology company redefining precision genomic medicines in vivo. Its proprietary Enveloped Delivery Vehicles (EDV) platform is engineered to deliver transient CRISPR-Cas9 cargo to specific cells in the body for site-specific genome editing with curative intent. Azalea’s first programs leverage T cell-targeting EDVs and highly efficient T cell-tropic AAVs to enable programmable CAR gene insertion at a defined genomic locus, placing expression under control of the cell’s endogenous promoter for physiologic and sustained activity.
Leadership & Board
- Current Number of Employees
- 34
- Current LinkedIn Followers
- 6,945
Latest Estimated Valuation
- Total Amount Raised
- $82M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $82M
- Latest Funding Round
- Series A
Employee Trend
Azalea Therapeutics had 34 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Azalea Therapeutics had 6,945 followers as of November 9, 2026. The number of followers increased by 74 (1.08%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Nov 04, 2025 | Series A | $82.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| RA Capital Management | Series A |
| Yosemite | Series A |
| Sozo Ventures | Series A |
| Third Rock Ventures | Series A |
Similar Companies
A snapshot of private companies similar to Azalea Therapeutics, helping you discover and navigate related company profiles.
